Engineered immune cells take on tough cancers in first human trial
Disease control
Not yet recruiting
This early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…
Phase: PHASE1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC